Navigation Links
Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
Date:12/5/2008

NEW BRUNSWICK, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today that its Development and License Agreement with the http://www.senesco.com ("Harris Moran") has been terminated by mutual agreement because of Harris Moran's recently announced corporate restructuring.

Harris Moran has reported that its parent company, Limagrain, restructured its vegetable seed operations and that Harris Moran will now be part of a new Business Unit with Clause (France) and Marco Polo (Thailand). This restructuring has resulted in a consolidation of R&D efforts amongst Harris Moran and its sister companies that will not encompass Senesco's technology. Harris Moran made Senesco aware of this shift in R&D focus and presented the Company with a letter on December 1, 2008 formally ending the relationship through the mutual agreement of the parties.

Pursuant to the terms of the Development and License Agreement all rights to use Senesco's technology in lettuce and melon revert to Senesco.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Company Contact:
    Senesco Technologies, Inc.
    Bruce Galton
    Chief Executive Officer
    (bgalton@senesco.com)
    (732) 296-8400

    Investor Relations Contact:
    FD
    Brian Ritchie
    (brian.ritchie@fd.com)
    (212) 850-5600


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
2. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
4. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
5. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
6. Senesco Technologies to Present at BIO 2008 Business Forum
7. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
8. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
9. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
10. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , ... at this year’s Bio-IT World Conference and Expo in Boston May 23-25 ... 4.0 solution. The Anzo Smart Data Lake is also a finalist for the ...
(Date:5/21/2017)... CA (PRWEB) , ... May 19, 2017 , ... ... annual meeting and educational conference of the American Association of Bioanalysts (AAB) and ... Galleria Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has added another ... a two-hour team-building package designed for groups of 10-30 people. Guests can ... include items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls with Pepperoni ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, is honored that Jay Crowley ... conference in Brussels, Belgium. , Crowley played a crucial role in the development ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):